Osamu Nomura 研究室

AI 要約（直近 5 年の研究成果）

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

研究成果（16 件）

• [2026] Predicting Clinical Response to Granulocyte/Monocyte Adsorption Apheresis in Treatment-Resistant Ulcerative Colitis
  DOI: https://doi.org/10.1016/j.gastha.2026.100922
• [2024] Residual Recurrence of a Small Intestinal Capillary Hemangioma with Obscure Gastrointestinal Bleeding Treated by Double-Balloon Endoscopy: A Case Report and Literature Review
  DOI: https://doi.org/10.3390/jcm13123415
• [2024] Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis: A Real-World Retrospective Study
  DOI: https://doi.org/10.3390/biomedicines12091991
• [2024] Remission Factors for Ustekinumab Treatment of Ulcerative Colitis: A Multicenter Retrospective Study of Real-World Data in Japan
  DOI: https://doi.org/10.3390/biomedicines12051119
• [2023] Small Intestinal Arteriovenous Malformation Treated by Double-balloon Endoscopy
  DOI: https://doi.org/10.2169/internalmedicine.2588-23
• [2023] Enterolith Treated with a Combination of Double-Balloon Endoscopy and Cola Dissolution Therapy
  DOI: https://doi.org/10.3390/medicina59030573
• [2023] Successful Treatment of Steroid-resistant Eosinophilic Gastrointestinal Disease with Mepolizumab
  DOI: https://doi.org/10.2169/internalmedicine.0801-22
• [2022] Differential diagnosis of ulcerative colitis with increased diarrhea; collagenous colitis or irritable bowel syndrome? A case report
  DOI: https://doi.org/10.1177/03000605221140686
• [2022] Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
  DOI: https://doi.org/10.3390/biomedicines10102526
• [2022] Enterocolic Lymphocytic Phlebitis Treated Preoperatively with Biologics and Immunosuppressive Agents
  DOI: https://doi.org/10.1155/2022/5120607

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。